Halozyme Therapeutics, Inc. (NASDAQ:HALO) had its price target boosted by equities researchers at Deutsche Bank AG to $20.00 in a report issued on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank AG’s target price would suggest a potential upside of 23.08% from the company’s current price.

Several other analysts have also issued reports on the stock. Piper Jaffray Companies increased their price target on shares of Halozyme Therapeutics from $20.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday. BidaskClub upgraded shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Friday, August 25th. Jefferies Group LLC restated an “underperform” rating and issued a $7.00 target price (up previously from $6.75) on shares of Halozyme Therapeutics in a research report on Thursday, August 10th. Finally, Canaccord Genuity set a $16.00 target price on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 26th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Halozyme Therapeutics presently has a consensus rating of “Hold” and an average target price of $16.00.

Halozyme Therapeutics (NASDAQ:HALO) traded up 1.69% on Friday, reaching $16.25. 5,824,402 shares of the company traded hands. The stock has a 50-day moving average of $12.79 and a 200 day moving average of $13.23. The company’s market capitalization is $2.18 billion. Halozyme Therapeutics has a 52-week low of $8.18 and a 52-week high of $16.65.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The firm had revenue of $33.80 million for the quarter, compared to analyst estimates of $31.76 million. The business’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.21) EPS. On average, equities analysts forecast that Halozyme Therapeutics will post ($0.88) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Halozyme Therapeutics, Inc. (HALO) PT Raised to $20.00 at Deutsche Bank AG” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/15/halozyme-therapeutics-inc-halo-pt-raised-to-20-00-at-deutsche-bank-ag.html.

Institutional investors have recently modified their holdings of the business. Ameritas Investment Partners Inc. acquired a new stake in Halozyme Therapeutics in the first quarter valued at approximately $122,000. Teacher Retirement System of Texas acquired a new stake in Halozyme Therapeutics in the second quarter valued at approximately $129,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Halozyme Therapeutics during the second quarter valued at $131,000. Prudential Financial Inc. raised its stake in shares of Halozyme Therapeutics by 8.7% during the second quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 940 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Halozyme Therapeutics during the second quarter valued at $171,000. Hedge funds and other institutional investors own 85.08% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.